Not a Member?
Email this page
Send the page ""
to a friend, relative, colleague or yourself.
Separate multiple email address with a comma
We do not record any personal information entered above.
Thank you. Your email has been sent.
Share this page
A recent push for judicious opioid prescribing and more appropriate stewardship of their use has been called for by the CDC. Fueled by increasingly concerning statistics, as well as a general increase in the use of opioids for the management of chronic pain, clinicians should always use great caution when initiating and managing opioid medications.
The greatest concern with opioid use, which is its overdose and addiction liability, is becoming profoundly more apparent. There were over 33,000 opioid-related deaths reported in 2015 alone, and since 2000, the rate of drug overdose deaths has increased by 137% with opioid-related deaths up by 200%.1,2 Due to the consequences of abuse, the FDA has for the first time taken steps to remove a currently marketed opioid pain medicine, Opana ER (oxymorphone hydrochloride), from sale.3
In their most recent publication regarding opioid use, the CDC provides multiple recommendations with respect to the initiation, selection, and monitoring of opioid use for chronic pain in patients. Listed are several key points:
To combat the opioid overdose epidemic, the FDA is also encouraging the development of opioids with abuse-deterrent properties. Several extended-release/long-acting opioids have been approved by the FDA with abuse-deterrent properties labeling. These opioid formulations deter improper use via nasal inhalation, crushing or IV use.4 While abuse-deterrent opioids may help combat misuse and abuse, it is important to note that these are not abuse-proof. For example, although Opana ER was specifically formulated to help prevent crushing and snorting of the medication, a review of postmarketing data showed a significant shift in the route of abuse of the product from nasal to injection after its reformulation.
Ultimately, practitioners must use proper judgment in the use of opioids for the management of pain. The utilization of non-opioids, nonpharmacologic therapy, patient history review and PDMPs, and good clinical practice can often significantly improve patient outcomes and experiences. Policies and positions on long-term opioid prescribing must also address the needs of patients with chronic pain who do benefit from the treatment and do not misuse the drugs. Further recommendations and clinical guidelines from the CDC are available.
Please update or register your profile to receive email alerts and other critical drug information updates from PDR. You can also stay current by using the official PDR app, available now for free from your favorite app stores.
References: 1) Drug Overdose Death Data. Centers for Disease Control and Prevention website. https://www.cdc.gov/drugoverdose/data/statedeaths.html. Updated December 16, 2016. Accessed July 14, 2017. 2) Increases in Drug and Opioid Overdose Deaths — United States, 2000–2014. Morbidity and Mortality Weekly Report, Centers for Disease Control and Prevention website. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6450a3.htm. Updated January 1, 2016. Accessed July 14, 2017. 3) FDA requests removal of Opana ER for risks related to abuse. U.S. Food and Drug Administration website. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm562401.htm. Updated June 6, 2017. Accessed July 14, 2017. 4) FDA Facts: Abuse-Deterrent Opioid Medications. U.S. Food and Drug Administration website. https://www.fda.gov/NewsEvents/Newsroom/FactSheets/ucm514939.htm. Updated April 21, 2017. Accessed July 14, 2017.